Our team has been making waves at the 34th ESCMID Global in Barcelona and the ATC2024 in Philadelphia with lively discussions around impressive AIC468 data at the respective poster sessions. AIC468 is a first-in-class antiviral antisense oligonucleotide in clinical development for the treatment of BKV infection in kidney transplant recipients. If you are interested to learn more about this promising program, you can download the presented posters here.